Biotron Ltd (BIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotron Ltd (BIT) has a cash flow conversion efficiency ratio of -0.322x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-868.42K ≈ $-614.46K USD) by net assets (AU$2.70 Million ≈ $1.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotron Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Biotron Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Biotron Ltd for a breakdown of total debt and financial obligations.
Biotron Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotron Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NCC Group plc
LSE:NCC
|
0.092x |
|
Star Fashion Culture Holdings Limited
NASDAQ:STFS
|
-0.479x |
|
Zenvia Inc
NASDAQ:ZENV
|
-0.034x |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
-0.002x |
|
Binect AG
XETRA:MA10
|
0.012x |
|
Polar Power Inc
NASDAQ:POLA
|
0.141x |
|
Global Sukses Solusi Tbk PT
JK:RUNS
|
-0.002x |
|
REGENCY SILVER CORP.
F:ZJ9
|
N/A |
Annual Cash Flow Conversion Efficiency for Biotron Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Biotron Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see BIT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$551.89K ≈ $390.50K |
AU$-565.80K ≈ $-400.34K |
-1.025x | -107.01% |
| 2024-06-30 | AU$-244.03K ≈ $-172.67K |
AU$-3.57 Million ≈ $-2.52 Million |
14.623x | +1510.16% |
| 2023-06-30 | AU$3.17 Million ≈ $2.24 Million |
AU$-3.29 Million ≈ $-2.33 Million |
-1.037x | +53.49% |
| 2022-06-30 | AU$1.09 Million ≈ $773.01K |
AU$-2.44 Million ≈ $-1.72 Million |
-2.230x | -152.78% |
| 2021-06-30 | AU$3.86 Million ≈ $2.73 Million |
AU$-3.41 Million ≈ $-2.41 Million |
-0.882x | -99.59% |
| 2020-06-30 | AU$6.97 Million ≈ $4.93 Million |
AU$-3.08 Million ≈ $-2.18 Million |
-0.442x | -60.48% |
| 2019-06-30 | AU$5.44 Million ≈ $3.85 Million |
AU$-1.50 Million ≈ $-1.06 Million |
-0.275x | +80.84% |
| 2018-06-30 | AU$1.28 Million ≈ $906.75K |
AU$-1.84 Million ≈ $-1.30 Million |
-1.437x | +26.95% |
| 2017-06-30 | AU$1.44 Million ≈ $1.02 Million |
AU$-2.83 Million ≈ $-2.00 Million |
-1.968x | -100.34% |
| 2016-06-30 | AU$3.14 Million ≈ $2.22 Million |
AU$-3.08 Million ≈ $-2.18 Million |
-0.982x | -49.61% |
| 2015-06-30 | AU$4.14 Million ≈ $2.93 Million |
AU$-2.72 Million ≈ $-1.92 Million |
-0.656x | +69.35% |
| 2014-06-30 | AU$1.39 Million ≈ $983.02K |
AU$-2.98 Million ≈ $-2.11 Million |
-2.142x | -210.15% |
| 2013-06-30 | AU$4.48 Million ≈ $3.17 Million |
AU$-3.09 Million ≈ $-2.19 Million |
-0.691x | -149.63% |
| 2012-06-30 | AU$8.27 Million ≈ $5.85 Million |
AU$-2.29 Million ≈ $-1.62 Million |
-0.277x | +66.27% |
| 2011-06-30 | AU$2.40 Million ≈ $1.70 Million |
AU$-1.97 Million ≈ $-1.39 Million |
-0.820x | +24.19% |
| 2010-06-30 | AU$1.72 Million ≈ $1.22 Million |
AU$-1.86 Million ≈ $-1.31 Million |
-1.082x | +51.88% |
| 2009-06-30 | AU$841.51K ≈ $595.42K |
AU$-1.89 Million ≈ $-1.34 Million |
-2.249x | -155.50% |
| 2008-06-30 | AU$1.84 Million ≈ $1.30 Million |
AU$-1.62 Million ≈ $-1.15 Million |
-0.880x | +67.26% |
| 2007-06-30 | AU$1.36 Million ≈ $959.47K |
AU$-3.65 Million ≈ $-2.58 Million |
-2.688x | -576.13% |
| 2006-06-30 | AU$4.50 Million ≈ $3.18 Million |
AU$-1.79 Million ≈ $-1.26 Million |
-0.398x | +47.04% |
| 2005-06-30 | AU$2.28 Million ≈ $1.61 Million |
AU$-1.71 Million ≈ $-1.21 Million |
-0.751x | +14.84% |
| 2004-06-30 | AU$2.96 Million ≈ $2.09 Million |
AU$-2.61 Million ≈ $-1.84 Million |
-0.882x | -344.86% |
| 2002-06-30 | AU$8.49 Million ≈ $6.01 Million |
AU$-1.68 Million ≈ $-1.19 Million |
-0.198x | -52.42% |
| 2001-06-30 | AU$10.08 Million ≈ $7.13 Million |
AU$-1.31 Million ≈ $-927.34K |
-0.130x | -- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.